10. シャルコー・マリー・トゥース病 Charcot-Marie-Tooth disease Clinical trials / Disease details

臨床試験数 : 41 / 薬物数 : 46 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15

diseases per page:

Showing 1 to 10 of 41 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05333406 (ClinicalTrials.gov)	February 22, 2022	6/1/2022	Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A	Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Pat ...	Charcot-Marie-Tooth Disease, Type IA	Drug: EN001	ENCell	NULL	Completed	19 Years	75 Years	All	9	Phase 1	Korea, Republic of
2	EUCTR2020-004805-30-DK (EUCTR)	31/01/2022	08/06/2021	Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ...	Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ...	Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclo ...	Pharnext SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	France;United States;Canada;Spain;Belgium;Denmark;Israel;Netherlands;Germany;Italy
3	EUCTR2020-004805-30-NL (EUCTR)	23/09/2021	27/05/2021	Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ...	Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ...	Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclo ...	Pharnext SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	France;United States;Canada;Spain;Belgium;Denmark;Israel;Germany;Netherlands;Italy
4	EUCTR2020-004805-30-IT (EUCTR)	19/05/2021	02/08/2021	Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ...	Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ...	Product Name: PXT3003 Product Code: [PXT3003] INN or Proposed INN: BACLOFENE INN or Proposed INN: NALTR ...	Pharnext SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	France;United States;Canada;Spain;Belgium;Denmark;Israel;Netherlands;Germany;Italy
5	EUCTR2020-004805-30-ES (EUCTR)	04/05/2021	30/07/2021	Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ...	Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ...	Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclo ...	Pharnext SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	France;United States;Canada;Belgium;Spain;Denmark;Israel;Netherlands;Germany;Italy
6	EUCTR2020-004805-30-FR (EUCTR)	04/05/2021	19/01/2022	Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patients	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, ...	Charcot Marie Tooth Type 1A MedDRA version: 20.0;Level: LLT;Classification code 10008414;Term: Charc ...	Product Name: NA Product Code: PXT3003 INN or Proposed INN: BACLOFEN Other descriptive name: (RS)-baclo ...	Pharnext SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	350	Phase 3	United States;France;Canada;Spain;Belgium;Denmark;Israel;Netherlands;Germany;Italy
7	NCT04762758 (ClinicalTrials.gov)	March 30, 2021	17/2/2021	Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients	A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, ...	Charcot-Marie-Tooth Disease	Drug: (RS)-baclofen, naltrexone hydrochloride and D-sorbitol;Drug: Placebo	Pharnext SA	Worldwide Clinical Trials	Active, not recruiting	16 Years	65 Years	All	350	Phase 3	United States;Belgium;Canada;Denmark;France;Germany;Israel;Italy;Spain;Netherlands
8	NCT05361031 (ClinicalTrials.gov)	September 21, 2020	31/3/2022	The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth DiseaseSubtype ...	Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial ...	CMT	Biological: Engensis (VM202)	Helixmith Co., Ltd.	NULL	Completed	19 Years	65 Years	All	12	Phase 1/Phase 2	Korea, Republic of
9	JPRN-jRCTs031190109	25/10/2019	03/10/2019	Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A	Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A - Ascorbic acid for CMT1A	Charcot-Marie-Tooth disease type 1A CMT1A;G600	ascorbic acid dayly intake	SHIOHAMA TADASHI	NULL	Recruiting	Not applicable	< 18age old	Both	12	Phase 2	Japan
10	JPRN-UMIN000036332	2019/06/15	28/03/2019	Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A	Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A - Ascorbic acid treatment for CMT1A	Charcot-Marie-Tooth diease type 1A	Ascorbic acid treatment: 20mg/kg/day, dayly	Chiba University	NULL	Pending	1years-old	Not applicable	Male and Female	10	Phase 1	Japan

First Previous1 2 3 4 5Next Last